Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPER trial
2018-004314-17Phase 2Unknown
- Sponsor
- The Christie
- Start
- Nov 2019
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and cyclophosphamide in clear cell renal cell carcinoma (ccRCC), sponsored by The Christie. Primary endpoint: Objective response rate. Status: unknown.
02
Drugs
pembrolizumabcyclophosphamide
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2018-004314-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004314-17.